Citation Impact
Citing Papers
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
Prospective identification of tumorigenic breast cancer cells
2003 Standout
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
2010
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Targeted therapies for breast cancer
2011
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial
2013
EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group
2019
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
2013
A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model
2007 StandoutNobel
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
De novo design of modular and tunable protein biosensors
2021 StandoutNatureNobel
Palindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumors
2017
The extracellular domain of Her2 in serum as a biomarker of breast cancer
2018
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Herceptin: mechanisms of action and resistance
2005
Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases
2016
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
2001
Neoadjuvant Therapy in the Treatment of Breast Cancer
2014
Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer
2000
Active myocardial damage without attending inflammatory response in dilated cardiomyopathy
1993
Breast cancer
2016 Standout
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
Carcinoma of the breast in males
1998
Ovarian cancer
2014 Standout
Role of Gemcitabine in Breast Cancer Management: An Update
2006
Optimal Chemotherapy Treatment for Women with Recurrent Ovarian Cancer
2007
Trastuzumab: triumphs and tribulations
2007
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
1998
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
2011 Standout
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
The role of chemokine activation of Rac GTPases in hematopoietic stem cell marrow homing, retention, and peripheral mobilization
2006
Clinical role of indium-111 antimyosin imaging
1991
Male breast carcinoma
1999
Antimyosin scintigraphy and immunohistologic analysis of endomyocardial biopsy in patients with clinically suspected myocarditis—evidence of myocardial cell damage and inflammation in the absence of histologic signs of myocarditis
1998
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Male breast cancer
2006 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer
2001
Cancer immunotherapy comes of age
2011 StandoutNature
Gastric cancer
2020 Standout
Myocarditis
2000 Standout
Adjuvant systemic therapy for male breast carcinoma
2005
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Cornerstones of CRISPR–Cas in drug discovery and therapy
2016 StandoutNobel
Detection of anthracycline-induced cardiotoxicity
1999
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Genes that mediate breast cancer metastasis to lung
2005 StandoutNature
Towards a targeted, risk‐based, antifungal strategy in neutropenic patients
2000
Epidermal growth factor receptor (EGFR) signaling in cancer
2005 Standout
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression
2014
Doxorubicin-Induced Cardiomyopathy
1998 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Preservation of Fertility in Patients with Cancer
2009 Standout
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
2007 Standout
Cancer of the Ovary
2004 Standout
A point mutation in the murine Hem1 gene reveals an essential role for Hematopoietic Protein 1 in lymphopoiesis and innate immunity
2008 StandoutNobel
TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data
2015 Standout
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
2003 Standout
Repeated observation of breast tumor subtypes in independent gene expression data sets
2003 Standout
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Surgical treatment of primary breast cancer in the neoadjuvant setting
2014
Prognostic Variables in Male Breast Cancer
2000
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
2001 Standout
Metabolic reprogramming and cancer progression
2020 StandoutScience
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis
2017 Standout
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2006 Standout
Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy.
2001
Preclinical characterisation of 111In‐DTPA‐trastuzumab
2004
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
2014 Standout
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Post-mastectomy radiation in male breast cancer
2002
Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial
2013
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Breast Cancer in Men
2002 Standout
Works of B. Ojeda being referenced
Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
2000
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
2014
Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies
1991
Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) study
2005
Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies.
1993
Male Breast Cancer Report of a Series of 50 Cases
1994
A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer
1995
Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation
1998
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
2010
Ovarian carcinoma preceded by cerebral metastasis: Review of the literature
1992
Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain
2004
Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients a randomized trial
1985
Paclitaxel plus doxorubicin in metastatic breast cancer: preliminary analysis of cardiotoxicity.
1997
Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer.
1990
Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer.
2013